Literature DB >> 9376590

Defective actin reorganization and polymerization of Wiskott-Aldrich T cells in response to CD3-mediated stimulation.

M D Gallego1, M Santamaría, J Peña, I J Molina.   

Abstract

The Wiskott-Aldrich syndrome (WAS) is a severe immunodeficiency and platelet deficiency disease arising from mutation(s) in the WASP gene, which in normal cells encodes an intracellular protein able to interact with other proteins relevant to the control of cytoskeleton organization. Immunodeficiency is mainly due to T-cell progressive malfunction. Salient defects of WAS T cells are a CD3-restricted impairment in proliferative responses and cytoskeletal abnormalities, including the frequent appearance of T cells with atypical morphology. We have investigated the possibility that the CD3-restricted defect and some of the cytoskeletal defects of WAS T cells are linked. For this purpose, we immortalized by means of infection with Herpesvirus Saimiri a number of previously described allospecific WAS T-cell lines. The resulting cells preserve the surface, molecular, and functional phenotypes of their parental lines, including a negligible WASP mRNA expression as well as the CD3-restricted defect and cytoskeleton abnormalities. Results show that, in CD3-stimulated WAS T cells, the pattern of temporal changes in cell shape and F-actin distribution is substantially different from that of control cells. Furthermore, polymerization of actin, a critical step in the CD3-mediated cytoskeleton reorganization, does not occur in WAS T-cell lines in response to OKT3 stimulation. In conclusion, our data link both CD3 and cytoskeletal defects in WAS T cells, strongly suggesting that cytoskeleton abnormalities are an underlying cause for WAS immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9376590

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  54 in total

Review 1.  The Wiskott-Aldrich syndrome.

Authors:  A J Thrasher; C Kinnon
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

2.  Modulation of HIV-1 replication by a novel RhoA effector activity.

Authors:  L Wang; H Zhang; P A Solski; M J Hart; C J Der; L Su
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

Review 3.  Wiskott-Aldrich syndrome: another piece in the puzzle.

Authors:  L D Notarangelo; L Mori
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

Review 4.  Regulation of cytoskeletal dynamics at the immune synapse: new stars join the actin troupe.

Authors:  Daniel D Billadeau; Janis K Burkhardt
Journal:  Traffic       Date:  2006-09-19       Impact factor: 6.215

Review 5.  Chemokines, their receptors and human disease: the good, the bad and the itchy.

Authors:  Vanessa L Bryant; Charlotte A Slade
Journal:  Immunol Cell Biol       Date:  2015-04       Impact factor: 5.126

Review 6.  Insights into primary immune deficiency from quantitative microscopy.

Authors:  Emily M Mace; Jordan S Orange
Journal:  J Allergy Clin Immunol       Date:  2015-06-13       Impact factor: 10.793

Review 7.  Herpesvirus saimiri.

Authors:  H Fickenscher; B Fleckenstein
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

8.  Haematopoietic lineage cell-specific protein 1 (HS1) promotes actin-related protein (Arp) 2/3 complex-mediated actin polymerization.

Authors:  Takehito Uruno; Peijun Zhang; Jiali Liu; Jian-Jiang Hao; Xi Zhan
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

9.  WIP is critical for T cell responsiveness to IL-2.

Authors:  Severine Le Bras; Michel Massaad; Suresh Koduru; Lalit Kumar; Michiko K Oyoshi; John Hartwig; Raif S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

Review 10.  Wiskott-Aldrich Syndrome: Immunodeficiency resulting from defective cell migration and impaired immunostimulatory activation.

Authors:  Gerben Bouma; Siobhan O Burns; Adrian J Thrasher
Journal:  Immunobiology       Date:  2009-07-22       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.